-
Intensive lipid lowering with statin therapy (atorvastatin 80 mg) in patients presenting with acute coronary syndromes (ACS) resulted in improved outcomes compared to treatment with moderate lipid lowering (pravastatin 40 mg) in the PROVE-IT TIMI-22 study (Cannon et al. N Engl J Med. 2004;350:1495-1504), which included patients treated conservatively, as well as those treated with percutaneous coronary intervention (PCI).
-
-
In the past nine months, the world has witnessed the outbreak of not one but two waves of pandemic influenza due to a new virus of swine origin. World public health authorities moved quickly to contain what appeared initially to be the severe pandemic that had been anticipated for so long.
-
-
-
Technological advances in medicine have the capability of helping health care providers to prolong life for patients faced with a terminal illness or injury.
-
Most physicians reported in a national survey that they would discuss end-of-life options with a terminally ill patient only when there were no more treatments to offer that patient not when the patient was still feeling well, according to a study published online in CANCER, a peer-reviewed journal of the American Cancer Society, in January.
-
As medical scientists and engineers in the health care arena pursue advances in drugs and technologies, is now the time to think more critically about these new technologies and how to address future implications for say, the ramifications of genetic screening and designer babies?
-
When the University of Michigan Health System's chief risk officer arrived in 2001, he had already mapped out to institutional leaders an architecture for risk management and medical error disclosure that would dramatically change the system's liability expenses, as well as its approach to patient safety.
-
Some of the thorniest questions that IRBs face are those for which there are no clear-cut answers opinions may vary, arguments on both sides may be compelling, regulatory guidance may be scanty.
